Rockwell Medical (RMTI) 10-Q 12 Nov 19 2019 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	9 Months Ended
	Sep. 30, 2019	Nov. 12, 2019
Document and Entity Information
Document Type	10-Q
Entity Registrant Name	ROCKWELL MEDICAL, INC.
Document Period End Date	Sep. 30, 2019
Entity Current Reporting Status	Yes
Entity Filer Category	Accelerated Filer
Entity Interactive Data Current	Yes
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		63,955,893
Entity Central Index Key	0001041024
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2019
Document Fiscal Period Focus	Q3
Amendment Flag	false

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)	Sep. 30, 2019	Dec. 31, 2018
ASSETS
Cash and Cash Equivalents	$ 14,421,394	$ 22,713,980
Investments Available-for -Sale	14,575,589	10,818,059
Accounts Receivable, net	5,122,453	6,979,514
Insurance Receivable		371,217
Inventory	3,583,452	4,038,778
Prepaid and Other Current Assets	2,861,708	1,903,682
Total Current Assets	40,564,596	46,825,230
Property and Equipment, net	2,506,093	2,638,293
Inventory, Non-Current	528,000	1,637,000
Right of Use Assets, net	3,011,805
Goodwill	920,745	920,745
Other Non-current Assets	555,933	536,516
Total Assets	48,087,172	52,557,784
LIABILITIES AND SHAREHOLDERS' EQUITY
Accounts Payable	3,194,039	4,492,071
Accrued Liabilities	3,916,069	5,129,761
Settlement Payable	270,000	416,668
Lease Liability - Current	1,482,441
Deferred License Revenue - Current	2,238,450	2,252,868
Insurance Financing Note Payable	1,145,133
Customer Deposits	48,163	63,143
Other Current Liability - Related Party	100,000	850,000
Total Current Liabilities	12,394,295	13,204,511
Lease Liability - Long-Term	1,589,098
Deferred License Revenue - Long-Term	10,401,166	12,076,399
Total Liabilities	24,384,559	25,280,910
Commitments and Contingencies (See Note 16)
Shareholders' Equity:
Preferred Shares, $.0001 par value, no shares issued and outstanding at September 30, 2019 and December 31, 2018
Common Shares, $.0001 par value; 170,000,000 shares authorized; 63,887,384 and 57,034,154 shares issued and outstanding at September 30, 2019 and December 31, 2018, respectively	6,389	5,703
Additional paid-in capital	322,837,353	299,596,257
Accumulated Deficit	(299,213,836)	(272,388,234)
Accumulated Other Comprehensive Income	72,707	63,148
Total Shareholders' Equity	23,702,613	27,276,874
Total Liabilities And Shareholders' Equity	$ 48,087,172	$ 52,557,784

CONDENSED CONSOLIDATED BALANC_2

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares	Sep. 30, 2019	Apr. 30, 2019	Dec. 31, 2018
CONDENSED CONSOLIDATED BALANCE SHEETS
Preferred Shares, par value (in dollars per share)	$ 0.0001		$ 0.0001
Preferred Shares, shares issued	0		0
Preferred Shares, shares outstanding	0		0
Common stock, no par value ( in dollars per share)	$ 0.0001		$ 0.0001
Common Shares, Shares Authorized	170,000,000		170,000,000
Common Shares, shares issued	63,887,384	437,043	57,034,154
Common Shares, shares outstanding	63,887,384		57,034,154

CONDENSED CONSOLIDATED STATEMEN

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
Net Sales	$ 15,407,248	$ 16,672,416	$ 45,812,475	$ 46,534,358
Cost of Sales	15,423,612	14,703,606	44,085,298	49,303,048
Gross Profit (Loss)	(16,364)	1,968,810	1,727,177	(2,768,690)
Selling and Marketing	1,827,473	121,874	7,148,848	716,414
General and Administrative	4,623,503	6,037,267	16,340,672	14,465,634
Settlement Expense			430,000	1,030,000
Research and Product Development	1,474,735	808,192	4,930,287	4,033,494
Operating Loss	(7,942,075)	(4,998,523)	(27,122,630)	(23,014,232)
Other Income
Realized Gain (Loss) on Investments	6,268	(97,027)	24,292	(222,014)
Interest Income	80,735	125,918	272,736	486,301
Total Other Income	87,003	28,891	297,028	264,287
Net Loss	$ (7,855,072)	$ (4,969,632)	$ (26,825,602)	$ (22,749,945)
Basic and Diluted Net Loss per Share	$ (0.12)	$ (0.10)	$ (0.45)	$ (0.44)
Basic and Diluted Weighted Average Shares Outstanding (in shares)	63,796,723	51,288,537	59,728,446	51,288,462

CONDENSED CONSOLIDATED STATEM_2

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS
Net Loss	$ (7,855,072)	$ (4,969,632)	$ (26,825,602)	$ (22,749,945)
Unrealized Gain on Available-for-Sale Debt Instrument Investments	5,926	143,868	10,190	96,327
Foreign Currency Translation Adjustments	(776)	(6,402)	(631)	(13,791)
Comprehensive Loss	$ (7,849,922)	$ (4,832,166)	$ (26,816,043)	$ (22,667,409)

CONDENSED CONSOLIDATED STATEM_3

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY - USD ($)	Public offeringCOMMON SHARES	Public offeringADDITIONAL PAID-IN CAPITAL	Public offering	At The Market [Member]COMMON SHARES	At The Market [Member]ADDITIONAL PAID-IN CAPITAL	At The Market [Member]	COMMON SHARES	ADDITIONAL PAID-IN CAPITAL	ACCUMULATED DEFICIT	ACCUMULATED OTHER COMPREHENSIVE INCOME	Total
Balance at Dec. 31, 2017							$ 5,177	$ 273,205,730	$ (240,262,376)	$ (35,383)	$ 32,913,148
Balance (in shares) at Dec. 31, 2017							51,768,424
Increase (Decrease) in Shareholders' Equity
Net Loss									(22,749,945)		(22,749,945)
Unrealized Gain on Available-for-Sale Investments										96,327	96,327
Foreign Currency Translation Adjustments										(13,791)	(13,791)
Amount of common stock issued on exercise of stock options								(1,978)			(1,978)
Exercise of Employee Stock Options (in shares)							870
Stock-based Compensation								2,425,919			2,425,919
Balance at Sep. 30, 2018							$ 5,177	275,629,671	(263,012,321)	47,153	12,669,680
Balance (in shares) at Sep. 30, 2018							51,769,294
Balance at Jun. 30, 2018							$ 5,177	275,017,065	(258,042,689)	(90,313)	16,889,240
Balance (in shares) at Jun. 30, 2018							51,768,424
Increase (Decrease) in Shareholders' Equity
Net Loss									(4,969,632)		(4,969,632)
Unrealized Gain on Available-for-Sale Investments										143,868	143,868
Foreign Currency Translation Adjustments										(6,402)	(6,402)
Amount of common stock issued on exercise of stock options								(1,978)			(1,978)
Exercise of Employee Stock Options (in shares)							870
Stock-based Compensation								614,584			614,584
Balance at Sep. 30, 2018							$ 5,177	275,629,671	(263,012,321)	47,153	12,669,680
Balance (in shares) at Sep. 30, 2018							51,769,294
Balance at Dec. 31, 2018							$ 5,703	299,596,257	(272,388,234)	63,148	$ 27,276,874
Balance (in shares) at Dec. 31, 2018							57,034,154				57,034,154
Increase (Decrease) in Shareholders' Equity
Net Loss									(26,825,602)		$ (26,825,602)
Unrealized Gain on Available-for-Sale Investments										10,190	10,190
Foreign Currency Translation Adjustments										(631)	(631)
Amount of common stock issued on exercise of stock options							$ 3	147,897			$ 147,900
Exercise of Employee Stock Options (in shares)							30,000				30,000
Delivery of common stock underlying restricted stock units, net of tax							$ 13	(180,302)			$ (180,289)
Delivery of common stock underlying restricted stock units, net of tax (in shares)							126,973
Issuance of Common Shares	$ 626	$ 17,289,296	$ 17,289,921	$ 44	$ 2,089,164	$ 2,089,208
Issuance of Common Shares (in shares)	6,259,214			437,043
Stock-based Compensation								3,895,041			3,895,041
Balance at Sep. 30, 2019							$ 6,389	322,837,353	(299,213,836)	72,707	$ 23,702,613
Balance (in shares) at Sep. 30, 2019							63,887,384				63,887,384
Balance at Jun. 30, 2019							$ 6,340	320,876,606	(291,358,764)	67,557	$ 29,591,739
Balance (in shares) at Jun. 30, 2019							63,398,704
Increase (Decrease) in Shareholders' Equity
Net Loss									(7,855,072)		(7,855,072)
Unrealized Gain on Available-for-Sale Investments										5,926	5,926
Foreign Currency Translation Adjustments										(776)	(776)
Delivery of common stock underlying restricted stock units, net of tax							$ 6	(84,866)			(84,860)
Delivery of common stock underlying restricted stock units, net of tax (in shares)							62,800
Issuance of Common Shares	$ 43	$ 1,169,199	$ 1,169,242
Issuance of Common Shares (in shares)	425,880
Stock-based Compensation								876,414			876,414
Balance at Sep. 30, 2019							$ 6,389	$ 322,837,353	$ (299,213,836)	$ 72,707	$ 23,702,613
Balance (in shares) at Sep. 30, 2019							63,887,384				63,887,384

CONDENSED CONSOLIDATED STATEM_4

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)	9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018
Cash Flows From Operating Activities:
Net Loss	$ (26,825,602)	$ (22,749,945)
Adjustments To Reconcile Net Loss To Net Cash Used In Operating Activities:
Depreciation and Amortization	581,982	466,994
Stock-based Compensation	3,895,041	2,425,919
Increase in Inventory Reserves	1,271,000	3,442,547
Amortization of Right of Use Asset	1,429,727
(Gain) Loss on Disposal of Assets	(620)	4,030
Realized (Gain) Loss on Sale of Investments Available-for-Sale	(24,292)	222,014
Foreign Currency Translation Adjustment	(631)	(13,791)
Changes in Assets and Liabilities:
Decrease (Increase) in Accounts Receivable, net	1,857,061	(1,226,133)
Decrease (Increase) in Insurance Receivable	371,217	(500,000)
Decrease in Inventory	293,326	3,669,233
Decrease in Other Assets	930,847	75,570
(Decrease) Increase in Accounts Payable	(1,298,031)	2,709,133
(Decrease) Increase in Settlement Payable	(146,668)	666,667
Decrease in Lease Liability	(1,369,994)
Decrease in Other Liabilities	(1,228,671)	(2,109,802)
Decrease in Deferred License Revenue	(1,689,651)	(1,718,127)
Changes in Assets and Liabilities	(2,280,564)	1,566,541
Cash Used In Operating Activities	(21,953,959)	(14,635,691)
Cash Flows From Investing Activities:
Purchase of Investments Available-for-Sale	(34,202,301)	(18,483,694)
Sale of Investments Available-for-Sale	30,479,252	29,596,315
Purchase of Equipment	(448,896)	(589,541)
Purchase of Research and Development Licenses (Related Party)	(750,000)
Cash (Used in) Provided By Investing Activities	(4,921,945)	10,523,080
Cash Flows From Financing Activities:
Payments on Short Term Notes Payable	(763,422)
Proceeds from the Exercise of Employee Stock Options	147,900
Stock Retained in Satisfaction of Tax Liabilities	180,289	1,978
Cash Provided By (Used In) Financing Activities	18,583,318	(1,978)
Decrease In Cash and Cash Equivalents	(8,292,586)	(4,114,589)
Cash At Beginning Of Period	22,713,980	8,406,917
Cash At End Of Period	14,421,394	$ 4,292,328
Supplemental Disclosure of Noncash Investing and Financing Activities:
Insurance Financing Note Payable	1,145,133
Public offering
Cash Flows From Financing Activities:
Proceeds from the issuance of common stock	18,777,642
Offering Costs from the Issuance of Common Stock	(1,487,721)
At The Market [Member]
Cash Flows From Financing Activities:
Proceeds from the issuance of common stock	2,296,235
Offering Costs from the Issuance of Common Stock	$ (207,027)

Description of Business

Description of Business	9 Months Ended
	Sep. 30, 2019
Description of Business
Description of Business	1. Description of Business Rockwell Medical, Inc. and subsidiaries (collectively, “we”, “our”, “us”, or the “Company”), is a biopharmaceutical company dedicated to improving outcomes for patients with anemia, with an initial focus on end-stage renal disease (ESRD). We are also a manufacturer of hemodialysis concentrates for dialysis providers and distributors in the United States and abroad. We supply the domestic market with dialysis concentrates and we also supply dialysis concentrates to distributors serving a number of foreign countries, primarily in the Americas and the Pacific Rim. Substantially, all of our sales have been concentrate products and ancillary items, though we initiated commercial sales of our proprietary therapeutic, Triferic, during the second quarter of 2019. Our mission is to transform anemia management in a wide variety of disease states across the globe while improving patients’ lives. Accordingly, we are building the foundation to become a leading medical and commercial organization in the field of dialysis. Triferic ® is a registered trademark of Rockwell Medical, Inc.

Going Concern

Going Concern	9 Months Ended
	Sep. 30, 2019
Going Concern
Going Concern	2. Going Concern As of September 30, 2019, the Company had approximately $14.4 million of cash and cash equivalents, $14.6 million of investments available-for-sale, working capital of $28.2 million and an accumulated deficit of $299.2 million. Net cash used in operating activities for the nine months ended September 30, 2019 was approximately $21.9 million. The Company will require significant additional capital to sustain its operations and make the investments it needs to execute its longer-term business plan. The Company’s existing liquidity is not sufficient to fund its operations and anticipated capital expenditures within one year of the issuance of the accompanying condensed consolidated financial statements. The Company’s recurring operating losses, net operating cash flow deficits, and an accumulated deficit, raise substantial doubt about the Company’s ability to continue as a going concern for one year from the issuance of the accompanying condensed consolidated financial statements. The condensed consolidated financial statements have been prepared assuming the Company will continue as a going concern. The Company has not made any adjustments to the accompanying condensed consolidated financial statements related to the recoverability and classification of recorded asset amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern. On June 20, 2019, the Company closed a public offering of 5,833,334 shares of common stock at a price of $3.00 per share. The aggregate proceeds from this public offering (net of the underwriters’ commissions and offering expenses) were approximately $16.1 million. On July 9, 2019, the underwriters of the public offering partially exercised their over-allotment option and purchased an additional 425,800 shares of common stock at a price of $3.00 per share, which closed on July 11, 2019. The aggregate proceeds from the exercise of the over-allotment option (net of the underwriters’ discount and offering expenses) were approximately $1.2 million. On March 22, 2019, the Company entered into a sales agreement with Cantor Fitzgerald & Co. (the “Agent”), pursuant to which the Company may offer and sell from time to time shares of the Company’s common stock through the Agent up to $40,000,000. As of September 30, 2019, approximately $37.7 million remains available for issuance under this facility. We are not required to sell any shares at any time during the term of the facility. Our ability to sell common stock under the facility may be limited by several factors including, among other things, the trading volume of our common stock and certain black-out periods that we may impose upon the facility, among other things. The Company will require additional capital to sustain its operations and make the investments it needs to execute upon its longer-term business plan, including the launch of Dialysate Triferic and I.V. Triferic. If the Company is unable to generate sufficient revenue from its existing long-term business plan, the Company will need to obtain additional equity or debt financing. If the Company attempts to obtain additional debt or equity financing, the Company cannot assume that such financing will be available on favorable terms, if at all.

Basis of Presentation, Summary

Basis of Presentation, Summary of Significant Accounting Policies and Recent Accounting Pronouncements	9 Months Ended
	Sep. 30, 2019
Basis of Presentation, Summary of Significant Accounting Policies and Recent Accounting Pronouncements
Basis of Presentation, Summary of Significant Accounting Policies and Recent Accounting Pronouncements	3. Basis of Presentation, Summary of Significant Accounting Policies and Recent Accounting Pronouncements At the 2019 Annual Meeting, the Company’s shareholders voted and approved to reincorporate the Company from the State of Michigan to the State of Delaware (the “Reincorporation”). The Reincorporation became effective on August 30, 2019 and was accomplished by the filing of (i) a certificate of conversion with the Bureau of Commercial Services of the Michigan Department of Labor & Economic Growth; (ii) a certificate of conversion with the Secretary of State of the State of Delaware; and (iii) a Certificate of Incorporation with the Secretary of State of the State of Delaware (the “Certificate of Incorporation”). The Company’s new authorized capital stock consists of 170,000,000 shares of common stock, $0.0001 par value per share, and 2,000,000 shares of preferred stock, $0.0001 par value per share. Certain reclassifications have been made to the 2018 financial statements and notes to conform to the 2019 presentation. The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with the accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information and pursuant to the instructions to Form 10-Q and Article 8 of Regulation S-X of the Securities and Exchange Commission (“SEC”) and on the same basis as the Company prepares its annual audited consolidated financial statements. In the opinion of management, the accompanying unaudited condensed consolidated financial statements reflect all adjustments, consisting of normal recurring adjustments, considered necessary for a fair presentation of such interim results. The results for the condensed consolidated statement of operations are not necessarily indicative of results to be expected for the year ending December 31, 2019 or for any future interim period. The condensed consolidated balance sheet at September 30, 2019 has been derived from unaudited financial statements; however, it does not include all of the information and notes required by U.S. GAAP for complete financial statements. The condensed consolidated balance sheet at December 31, 2018 has been derived from audited financial statements, however, it does not include all of the information and notes required by U.S. GAAP for complete financial statements. The accompanying condensed consolidated financial statements should be read in conjunction with the consolidated financial statements for the year ended December 31, 2018 and notes thereto included in the Company’s annual report on Form 10-K filed on March 18, 2019. The accompanying condensed consolidated interim financial statements include the accounts of the Company and its subsidiaries. All intercompany balances and transactions have been eliminated in consolidation. Use of Estimates The preparation of the condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that may affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of expenses during the reporting period. Actual results could differ from those estimates. Significant Accounting Policies With the exception of the adoption of ASU 2016-02 relating to accounting for leases, there have been no material changes in the Company’s significant accounting policies as previously disclosed in the Company’s Annual Report on Form 10-K for the year ended December 31, 2018. Leases Effective January 1, 2019, the Company accounts for its leases under Accounting Standards Codification (“ASC”) 842, Leases . Under this guidance, arrangements meeting the definition of a lease are classified as operating or financing leases and are recorded on the consolidated balance sheet as both a right-of-use asset and lease liability, calculated by discounting fixed lease payments over the lease term at the rate implicit in the lease or the Company’s incremental borrowing rate. Lease liabilities are increased by interest and reduced by payments each period, and the right-of-use asset is amortized over the lease term. For operating leases, interest on the lease liability and the amortization of the right-of-use asset result in straight-line rent expense over the lease term. Variable lease expenses, if any, are recorded when incurred. In calculating the right-of-use asset and lease liability, the Company elects to combine lease and non-lease components. The Company excludes short-term leases having initial terms of 12 months or less from the new guidance as an accounting policy election and recognizes rent expense on a straight-line basis over the lease term. The Company continues to account for leases in the prior period financial statements in accordance with ASC Topic 840. Loss Per Share ASC 260, Earnings Per Share, requires dual presentation of basic and diluted earnings per share (“EPS”), with a reconciliation of the numerator and denominator of the basic EPS computation to the numerator and denominator of the diluted EPS computation. Basic EPS excludes dilution. Diluted EPS reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common stock or resulted in the issuance of common stock that are then sharing in the earnings of the entity. Basic net loss per share of common stock excludes dilution and is computed by dividing the net loss by the weighted average number of shares outstanding during the period. Diluted net loss per share of common stock reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common stock or resulted in the issuance of common stock that then shared in the earnings of the entity unless inclusion of such shares would be anti-dilutive. The Company has only incurred losses, therefore, basic and diluted net loss per share is the same. Securities that could potentially dilute net income per share in the future that were not included in the computation of diluted loss per share were as follows: As of September 30, 2019 2018 Options to purchase common stock 8,170,382 8,048,105 Unvested restricted stock awards 146,800 146,800 Unvested restricted stock units 1,324,172 1,293,750 Warrants to purchase common stock 2,770,781 - 12,412,135 9,488,655 Adoption of Recent Accounting Pronouncements The Company continually assesses any new accounting pronouncements to determine their applicability. When it is determined that a new accounting pronouncement affects the Company’s financial reporting, the Company undertakes a review to determine the consequences of the change to its consolidated financial statements and assures that there are sufficient controls in place to ascertain that the Company’s consolidated financial statements properly reflect the change. In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842) , which amended the guidance on accounting for leases. The FASB issued this update to increase transparency and comparability among organizations. This update requires the recognition of lease assets and lease liabilities on the balance sheet and the disclosure of key information about leasing arrangements. The Company adopted this ASU effective January 1, 2019 using the additional (optional) approach by recording a right-of-use asset and a lease liability of approximately $3.5 million. Our adoption of this ASU had no effect on opening retained earnings, and the Company continues to account for leases in the prior period consolidated financial statements under ASC Topic 840. In adopting the new standard, the Company elected to apply the practical expedients regarding identification of leases, lease classification, indirect costs, and the combination of lease and non-lease components. In June 2018, the FASB issued ASU 2018-17, Improvements to Nonemployee Share-Based Payment Accounting, which simplifies the accounting for share-based payments granted to nonemployees for goods and services. Under ASU 2018-17, most of the guidance on such payments to nonemployees would be aligned with the requirements for share-based payments granted to employees. The amendments are effective for fiscal years beginning after December 15, 2019, and interim periods within fiscal years beginning after December 15, 2020. Early adoption is permitted, but no earlier than an entity’s adoption of Topic 606. The Company adopted this new standard on January 1, 2019 and the adoption did not have a material impact on its condensed consolidated financial statements and related disclosures.

Revenue Recognition

Revenue Recognition	9 Months Ended
	Sep. 30, 2019
Revenue Recognition
Revenue Recognition	4. Revenue Recognition The Company recognizes revenue under ASC 606, Revenue from Contracts with Customers. The core principle of the new revenue standard is that a company should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. The following five steps are applied to achieve that core principle: · Step 1: Identify the contract with the customer · Step 2: Identify the performance obligations in the contract · Step 3: Determine the transaction price · Step 4: Allocate the transaction price to the performance obligations in the contract · Step 5: Recognize revenue when the company satisfies a performance obligation Taxes assessed by a governmental authority that are both imposed on and concurrent with a specific revenue-producing transaction, that are collected by us from a customer, are excluded from revenue. Shipping and handling costs associated with outbound freight related to contracts with customers are accounted for as a fulfillment cost and are included in cost of sales when control of the goods transfers to the customer. Nature of goods and services The following is a description of principal activities from which the Company generates its revenue. Product sales – The Company accounts for individual products and services separately if they are distinct (i.e., if a product or service is separately identifiable from other items and if a customer can benefit from it on its own or with other resources that are readily available to the customer). The consideration, including any discounts, is allocated between separate products and services based on their stand-alone selling prices. The stand-alone selling prices are determined based on the cost plus margin approach. Drug and dialysis concentrate products are sold directly to dialysis clinics and to wholesale distributors in both domestic and international markets. Distribution and license agreements for which upfront fees are received are evaluated upon execution or modification of the agreement to determine if the agreement creates a separate performance obligation from the underlying product sales. For all existing distribution and license agreements, the distribution and license agreement is not a distinct performance obligation from the product sales. In instances where regulatory approval of the product has not been established and the Company does not have sufficient experience with the foreign regulatory body to conclude that regulatory approval is probable, the revenue for the performance obligation is recognized over the term of the license agreement (over time recognition). Conversely, when regulatory approval already exists or is probable, revenue is recognized at the point in time that control of the product transfers to the customer. The Company received upfront fees under two distribution and license agreements that have been deferred as a contract liability. The amounts received from Wanbang Biopharmaceuticals Co., Ltd. (“Wanbang”) are recognized as revenue over the estimated term of the distribution and license agreement as regulatory approval was not received and the Company did not have sufficient experience in China to determine that regulatory approval was probable as of the execution of the agreement. The amounts received from Baxter Healthcare Corporation (“Baxter”), are recognized as revenue at the point in time that the estimated product sales under the agreement occur. For the majority of the Company’s international customers, the Company recognizes revenue at the shipping point, which is generally the Company’s plant or warehouse. For other business, including the business under the Company’s distribution agreement with Baxter (the “Baxter Agreement”), the Company recognizes revenue based on when the customer takes control or receipt of the product. The amount of revenue recognized is based on the purchase order less returns and adjusted for any rebates, discounts, chargebacks or other amounts paid to customers. There were no such adjustments for the periods reported. Customers typically pay for the product based on customary business practices with payment terms averaging 30 days, while distributor payment terms average 45 days. Disaggregation of revenue Revenue is disaggregated by primary geographical market, major product line, and timing of revenue recognition. In thousands of US dollars ($) Three Months Ended September 30, 2019 Nine Months Ended September 30, 2019 Products By Geographic Area Total U.S. Rest of World Total U.S. Rest of World Drug Revenues Product Sales – Point-in-time $ 98 $ 98 $ - $ 112 $ 112 $ - License Fee – Over time 68 - 68 205 - 205 Total Drug Products 166 98 68 317 112 205 Concentrate Products Product Sales – Point-in-time 14,746 13,353 1,393 44,010 39,100 4,910 License Fee – Over time 495 495 - 1,485 1,485 - Total Concentrate Products 15,241 13,848 1,393 45,495 40,585 4,910 Net Revenue $ 15,407 $ 13,946 $ 1,461 $ 45,812 $ 40,697 $ 5,115 Three Months Ended September 30, 2018 Nine Months Ended September 30, 2018 Products By Geographic Area Total U.S. Rest of World Total U.S. Rest of World Drug Revenues License Fee – Over time $ 68 - $ 68 $ 205 - $ 205 Concentrate Products Product Sales – Point-in-time 16,099 13,208 2,891 44,815 38,536 6,279 License Fee – Over time 505 505 - 1,514 1,514 - Total Concentrate Products 16,604 13,713 2,891 46,329 40,050 6,279 Net Revenue $ 16,672 $ 13,713 $ 2,959 $ 46,534 $ 40,050 $ 6,484 Contract balances The following table provides information about receivables, contract assets, and contract liabilities from contracts with customers. In thousands of US dollars ($) September 30, 2019 December 31, 2018 Receivables, which are included in "Trade and other receivables" $ 5,122 $ 6,980 Contract liabilities $ 12,640 $ 14,329 There were no impairment losses recognized related to any receivables arising from the Company’s contracts with customers for the three and nine months ended September 30, 2019 and 2018. For the three and nine months ended September 30, 2019 and September 30, 2018, the Company did not recognize material bad-debt expense and there were no material contract assets recorded on the condensed consolidated balance sheet as of September 30, 2019 and December 31, 2018. The Company does not generally accept returns of its concentrate products and no reserve for returns of concentrate products was established as of September 30, 2019 or December 31, 2018. The contract liabilities primarily relate to upfront payments and consideration received from customers that are received in advance of the customer assuming control of the related products. Transaction price allocated to remaining performance obligations For the three and nine months ended September 30, 2019, revenue recognized from performance obligations related to prior periods was not material. Revenue expected to be recognized in any future year related to remaining performance obligations, excluding revenue pertaining to contracts that have an original expected duration of one year or less, contracts where revenue is recognized as invoiced and contracts with variable consideration related to undelivered performance obligations, totaled $10.4 million as of September 30, 2019. The amount relates primarily to upfront payments and consideration received from customers that are received in advance of the customer assuming control of the related products. The Company applies the practical expedient in paragraph 606-10-50-14 and does not disclose information about remaining performance obligations that have original expected durations of one year or less. The Baxter Agreement includes minimum commitments of product sales over the duration of the agreement. Unfulfilled performance obligations related to the Baxter Agreement are product sales of $9.6 million, which will be amortized through expiration of the agreement on October 2, 2024.

Investments - Available-for-Sal

Investments - Available-for-Sale	9 Months Ended
	Sep. 30, 2019
Investments - Available-for-Sale
Investments - Available-for-Sale	5. Investments - Available-for-Sale Investments available-for-sale consisted of the following as of September 30, 2019 and December 31, 2018: September 30, 2019 Amortized Cost Unrealized Gain Unrealized Loss Fair Value Available-for-Sale Securities Bonds $ 14,549,799 $ 26,401 $ (611) $ 14,575,589 December 31, 2018 Amortized Cost Unrealized Gain Unrealized Loss Fair Value Available-for-Sale Securities Bonds $ 10,801,836 $ 17,415 $ (1,192) $ 10,818,059 The fair value of investments available-for-sale are determined using quoted market prices from daily exchange-traded markets based on the closing price as of the balance sheet date and are classified as Level 1, as described in Note 3 on Form 10-K, Fair Value Measurement to our condensed consolidated financial statements. As of September 30, 2019 and December 31, 2018, available-for-sale securities were due in one year or less.

Inventory

Inventory	9 Months Ended
	Sep. 30, 2019
Inventory
Inventory	6. Inventory Components of inventory, net of reserves as of September 30, 2019 and December 31, 2018 are as follows: September 30, December 31, 2019 2018 Raw Materials $ 2,390,179 $ 3,621,548 Work in Process 209,940 256,129 Finished Goods 1,511,333 1,798,101 Total $ 4,111,452 $ 5,675,778 As of September 30, 2019 and December 31, 2018, we classified $0.5 million and $1.6 million, respectively, of inventory as non-current, all of which was related to Triferic or the active pharmaceutical ingredient (API) for Triferic. As of September 30, 2019 and December 31, 2018, we had total Triferic inventory aggregating $3.5 million and $8.0 million respectively, against which we had reserved $2.8 million and $5.8 million respectively. The $0.7 million net value of Triferic inventory consisted of $0.1 million of Dialysate Triferic finished goods with expiration dates ranging from March 2020 to May 2021, and $0.6 million of Triferic API with estimated useful lives extending through 2023. The Company increased its inventory reserve for Triferic by $1.1 million as of September 30, 2019 due to, among other factors, the impact of the Centers for Medicare & Medicaid Services (“CMS”) Final Rule, which is discussed in Note 17 below, and its current volume forecasts for Triferic across the globe.

Property And Equipment

Property And Equipment	9 Months Ended
	Sep. 30, 2019
Property and Equipment
Property and Equipment	7. Property and Equipment As of September 30, 2019 and December 31 2018, the Company’s property and equipment consisted of the following: September 30, December 31, 2019 2018 Leasehold Improvements $ 1,114,503 $ 929,849 Machinery and Equipment 4,719,132 4,800,774 Information Technology & Office Equipment 1,810,246 2,459,832 Laboratory Equipment 653,075 668,977 8,296,956 8,859,432 Accumulated Depreciation (5,790,863) (6,221,139) Net Property and Equipment $ 2,506,093 $ 2,638,293 Depreciation expense for the three months ended September 30, 2019 and 2018, totaled $0.2 million and $0.2 million, respectively. Depreciation expense for the nine months ended September 30, 2019 and 2018, totaled $0.58 million and $0.47 million, respectively.

Accrued Liabilities

Accrued Liabilities	9 Months Ended
	Sep. 30, 2019
Accrued Liabilities
Accrued Liabilities	8. Accrued Liabilities Accrued liabilities as of September 30, 2019 and December 31, 2018 consisted of the following: September 30, December 31, 2019 2018 Accrued Research & Development Expense $ 84,798 $ 86,820 Accrued Compensation and Benefits 1,334,563 1,525,599 Accrued Legal Expenses 392,869 170,334 Accrued Marketing Expenses 206,649 5,000 Other Accrued Liabilities 1,897,190 3,342,008 Total Accrued Liabilities $ 3,916,069 $ 5,129,761

Insurance Financing Note Payabl

Insurance Financing Note Payable	9 Months Ended
	Sep. 30, 2019
Insurance Financing Note Payable [Abstract]
Insurance Financing Note Payable	9. Insurance Financing Note Payable On June 3, 2019, the Company entered into a short-term note payable for $1.9 million, bearing interest at 4.65% per annum to finance various insurance policies. Principal and interest payments related to this note began on July 3, 2019 and are paid on a straight-line amortization over a 10-month period with the final payment due on April 3, 2020. As of September 30, 2019, the Company’s insurance note payable balance was $1.15 million.

Deferred Revenue

Deferred Revenue	9 Months Ended
	Sep. 30, 2019
Revenue Recognition
Deferred Revenue	10. Deferred Revenue In October of 2014, the Company entered into a 10 year distribution agreement with Baxter and received an upfront fee of $20 million. The upfront fee was recorded as deferred revenue and is being recognized based on the proportion of product shipments to Baxter in each period, compared with total expected sales volume over the term of the Baxter Agreement. The Company recognized revenue of approximately $0.5 million and $1.5 million during the three and nine months ended September 30, 2019 and 2018, respectively. Deferred revenue related to the Baxter Agreement totaled $9.6 million as of September 30, 2019 and $11.1 million as of December 31, 2018. If a “Refund Trigger Event” occurs, we would be obligated to repay a portion of the upfront fee and any paid portion of the facility fee. In the event of a Refund Trigger Event occurring from January 1, 2019 to December 31, 2021, Baxter would be eligible for a 25% refund of the Agreement’s Upfront Payment. In addition, if Baxter terminates the Agreement because Baxter has been enjoined by a court of competent jurisdiction from selling in the United States any product covered by the Baxter Agreement due to a claim of intellectual property infringement or misappropriation relating to such product prior to the end of 2019, Baxter would be eligible for a partial refund of $6.6 million. In no event would more than one refund be required to be paid. During the year ended December 31, 2016, the Company entered into a distribution and license agreement with Wanbang and received an upfront fee of $4.0 million. The upfront fee was recorded as deferred revenue and is being recognized as revenue based on the agreement term. The Company recognized revenue of approximately $0.1 million and $0.2 million during the three and nine months ended September 30, 2019 and 2018, respectively. Deferred revenue related to the Wanbang agreement totaled $3.0 million as of September 30, 2019 and $3.2 million as of December 31, 2018.

Stockholders' Equity

Stockholders' Equity	9 Months Ended
	Sep. 30, 2019
Stockholders' Equity
Stockholders' Equity	11. Shareholders’ Equity At the 2019 Annual Meeting, the Company’s shareholders voted and approved to reincorporate the Company from the State of Michigan to the State of Delaware (the “Reincorporation”). The Reincorporation became effective on August 30, 2019 and was accomplished by the filing of (i) a certificate of conversion with the Bureau of Commercial Services of the Michigan Department of Labor & Economic Growth; (ii) a certificate of conversion with the Secretary of State of the State of Delaware; and (iii) a Certificate of Incorporation with the Secretary of State of the State of Delaware (the “ Certificate of Incorporation ”). The Company’s new authorized capital stock consists of 170,000,000 shares of common stock, $0.0001 par value per share, and 2,000,000 shares of preferred stock, $0.0001 par value per share. Preferred Stock As of September 30, 2019 and December 31, 2018, there were 2,000,000 shares of preferred stock authorized and no shares of preferred stock issued or outstanding. Common Stock As of September 30, 2019, the Company’s authorized shares of common stock was 170 million shares. On June 6, 2019, the Company obtained shareholder approval to increase the number of authorized shares of the Company’s common stock by 50 million shares from 120 million shares to 170 million shares. On July 30, 2019, the Company amended its Articles of Incorporation to reflect this increase in authorized shares from 120 million to 170 million shares. During the nine months ended September 30, 2019, 30,000 vested employee stock options were exercised for cash proceeds of $147,900, at a weighted average exercise price of $4.93. Controlled Equity Offering On March 22, 2019, the Company entered into a sales agreement (the “Sales Agreement”) with Cantor Fitzgerald & Co. (the “Agent”), pursuant to which the Company may offer and sell from time to time shares of the Company’s common stock through the Agent. The offering and sale of up to $40,000,000 of the shares has been registered under the Securities Act of 1933, as amended, pursuant to the Company’s registration statement on Form S-3 (File No. 333-227363), which was originally filed with the SEC on September 14, 2018 and declared effective by the SEC on October 1, 2018. The base prospectus contained within the registration statement, and a prospectus supplement was filed with the SEC on March 22, 2019. Sales of the shares, if any, pursuant to the Sales Agreement, may be made in sales deemed to be a “at the market offering” as defined in Rule 415(a) of the Securities Act, including sales made directly through the Nasdaq Global Market or on any other existing trading market for the Company’s common stock. The Company intends to use the proceeds from the offering for working capital and other general corporate purposes. The Company may suspend or terminate the Sales Agreement at any time. In April 2019, the Company sold 437,043 shares of its common stock pursuant to the Sales Agreement for gross proceeds of $2,296,235, at a weighted average selling price of approximately $5.25. The Company paid $207,027 in commissions and offering fees related to the sale of the common shares. As of September 30, 2019, approximately $37.7 million remains available for issuance under this facility. We are not required to sell any shares at any time during the term of the facility. Our ability to sell common stock under the facility may be limited by several factors including, among other things, the trading volume of our common stock and certain black-out periods that we may impose upon the facility, among other things. Public Offering of Common Stock On June 17, 2019, the Company entered into a purchase agreement with Piper Jaffray & Co., and Cantor Fitzgerald & Co, pursuant to which the Company agreed to issue and sell up to 6,708,334 shares of common stock, which included 875,000 optional shares that may be sold pursuant to an option granted to the underwriters. On June 20, 2019, the Company closed the sale of 5,833,334 shares of its common stock for gross proceeds of $17,500,002 at the public offering price of $3.00 per share (the “Offering”). The Company paid $1,379,323 in underwriters’ commissions and fees related to the sale of the common shares. The Offering was made pursuant to the Company’s effective registration statement on Form S-3 (File No. 333-227363), which was previously filed with the SEC. On July 9, 2019, the Underwriters exercised their over-allotment option to purchase an additional 425,800 shares of common stock at a price of $3.00 per share, which closed on July 11, 2019. The total proceeds to the Company (net of underwriting commissions and offering fees) from the exercise of the over-allotment option were approximately $1.2 million. Restricted Common Stock During the nine months ended September 30, 2019, 195,042 shares of common stock related to fully vested restricted stock units were delivered to an officer of the Company. The Company withheld 68,069 of these common shares at a fair value of $180,289 to cover the officer’s withholding taxes related to the vesting of restricted stock units.

Stock-Based Compensation

Stock-Based Compensation	9 Months Ended
	Sep. 30, 2019
Stock-Based Compensation
Stock-Based Compensation	12. Stock-Based Compensation The Company recognized total stock-based compensation expense during the three and nine months ended September 30, 2019 and 2018 as follows: Three Months Ended Nine Months Ended September 30, September 30, 2019 2018 2019 2018 Service based awards: Restricted stock awards $ - $ 20,222 $ - $ 1,292,125 Restricted stock units 502,080 166,417 1,273,903 166,417 Stock option awards 596,657 427,944 1,795,819 967,377 1,098,737 614,583 3,069,722 2,425,919 Performance based awards: Restricted stock units (332,389) - 468,814 - Stock option awards 110,065 - 356,505 - (222,324) - 825,319 - Total $ 876,413 $ 614,583 $ 3,895,041 $ 2,425,919 The decrease in stock-based compensation associated with performance based awards for restricted stock units is the result of a change in vesting criteria from probable to improbable based on the CMS Final Rule as described in Note 17 below. This change resulted in a reduction of stock-based compensation expense of $0.7 million for the three and nine months ended September 30, 2019. Restricted Stock A summary of the Company’s restricted stock awards during the nine months ended September 30, 2019 is as follows: Weighted Average Grant-Date Number of Shares Fair Value Unvested at December 31, 2018 $ 5.70 Unvested at September 30, 2019 $ 5.70 A summary of the Company’s restricted stock awards during the nine months ended September 30, 2018 is as follows: Weighted Average Grant-Date Number of Shares Fair Value Unvested at December 31, 2017 480,000 $ 7.27 Forfeited (333,200) 5.70 Unvested at September 30, 2018 146,800 $ 5.70 The fair value of restricted stock awards are measured based on their fair value on the date of grant and amortized over the vesting period of 20 months. As of September 30, 2019 unvested restricted stock awards of 146,800 were related to performance based awards. Service Based Restricted Stock Units A summary of the Company’s service based restricted stock units during the nine months ended September 30, 2019 is as follows: Weighted Average Grant-Date Number of Shares Fair Value Unvested at December 31, 2018 472,959 $ 4.32 Granted 222,497 4.26 Forfeited (4,950) 4.81 Vested (96,542) 4.70 Unvested at September 30, 2019 593,964 $ 4.23 The fair value of service based restricted stock units are measured based on their fair value on the date of grant and amortized over the vesting period. The vesting periods range from 1-3 years. Stock-based compensation expense of $0.5 million and $1.3 million was recognized during the three and nine months ended September 30, 2019. Stock-based compensation expense of $0.2 million was recognized for each of three and nine months ended September 30, 2018. As of September 30, 2019, the unrecognized stock-based compensation expense was $1.3 million. Performance Based Restricted Stock Units A summary of the Company’s performance based restricted stock units during the nine months ended September 30, 2019 is as follows: Weighted Average Grant-Date Number of Shares Fair Value Unvested at December 31, 2018 988,958 $ 4.48 Unvested at September 30, 2019 988,958 $ 4.48 Stock-based compensation expense recognized for performance based restricted stock units was ($0.3) million and $0.5 million during the three and nine months ended September 30, 2019. The Company did not record stock-based compensation expenses related to the performance-based grants as of September 30, 2018. As of September 30, 2019, the unrecognized stock-based compensation expense related to performance based restricted stock units was $1.0 million. The performance based restricted stock unit compensation was reduced by $0.7 million for the three and nine months ended September 30, 2019 due to a change in vesting criteria from probable to improbable for certain performance based awards. The Company will continue to review this performance award criteria and recognize compensation costs as it relates to the probability of vesting. Service Based Stock Options The fair value of the service based stock options granted for the nine months ended September 30, 2019 were based on the following assumptions: Nine Months Ended September 30, 2019 2018 Exercise price $2.39 - $6.21 $4.52 - $5.75 Expected stock price volatility 67.5% - 70.3% 67.5% Risk-free interest rate 1.4% - 2.6% 2.7% - 2.9% Term (years) 5.25 - 6.5 5.0 - 6.5 A summary of the Company’s service based stock option activity for the nine months ended September 30, 2019 is as follows: Weighted Weighted Average Shares Average Remaining Aggregate Underlying Exercise Contractual Intrinsic Options Price Term Value Outstanding at December 31, 2018 7,856,480 $ 7.50 5.2 $ - Granted 576,477 4.17 9.2 12,074 Exercised (30,000) 4.93 - - Forfeited (620,700) 6.34 - - Outstanding at September 30, 2019 7,782,257 $ 7.35 5.1 $ 12,074 Exercisable at September 30, 2019 6,340,901 $ 8.07 4.2 $ - A summary of the Company’s service based stock option activity for the nine months ended September 30, 2018 is as follows: Weighted Weighted Average Shares Average Remaining Aggregate Underlying Exercise Contractual Intrinsic Options Price Term Value Outstanding at December 31, 2017 6,906,001 $ 7.92 5.0 $ 976,335 Granted 1,337,271 4.96 9.4 Exercised (5,000) 6.59 - Forfeited (190,167) 6.59 - Outstanding at September 30, 2018 8,048,105 $ 7.46 5.2 $ 365,135 Exercisable at September 30, 2018 6,248,160 $ 7.90 4.1 $ 365,135 The aggregate intrinsic value in the table above is calculated as the difference between the closing price of our common stock and the exercise price of the stock options that had strike prices below the closing price. During the nine months ended September 30, 2019, the Company granted to certain employees stock options to purchase up to 576,477 shares of common stock. During the nine months ended September 30, 2019, forfeitures were 620,700. Forfeitures are recorded in the period of occurrence; compensation expense is adjusted accordingly. Stock-based compensation expense recognized for service based stock options was $0.6 million and $1.8 million for the three and nine months ended September 30, 2019 and $0.4 million and $1.0 million for the three and nine months ended September 30, 2018. As of September 30, 2019, total stock-based compensation expense related to unvested options not yet recognized totaled approximately $2.1 million. Performance Based Stock Options A summary of the performance based stock options for the nine months ended September 30, 2019, is as follows: Weighted Average Exercise Number of Shares Price Outstanding at December 31, 2018 388,125 $ 4.70 Outstanding at September 30, 2019 388,125 $ 4.70 Exercisable at September 30, 2019 - $ - Stock-based compensation expense recognized for performance based stock options was $0.1 million and $0.4 million during the three and nine months ended September 30, 2019. Stock-based compensation expense recognized for performance based stock options was $51,000 for each of the three and nine months ended September 30, 2018. As of September 30, 2019, the unrecognized stock-based compensation expense related to performance based stock options was $0.6 million.

Related Party Transactions

Related Party Transactions	9 Months Ended
	Sep. 30, 2019
Related Party Transactions
Related Party Transactions	13. Related Party Transactions Product License Agreements The Company is a party to an in-license agreement for exclusive worldwide rights to certain patents and information related to our Triferic® product. On October 7, 2018, the Company entered into a Master Services and IP Agreement (the “Charak MSA”) with Charak, LLC and Dr. Ajay Gupta (collectively “Charak”), who serves as Executive Vice President and Chief Scientific Officer of the Company. Pursuant to the MSA, the parties entered into three additional agreements described below related to the license of certain soluble ferric pyrophosphate (“SFP”) intellectual property owned by Charak, as well as the Employment Agreement (defined below). The Charak MSA provides for a payment of $1.0 million to Dr. Gupta, payable in four quarterly installments of $250,000 each on October 15, 2018, January 15, 2019, April 15, 2019 and July 15, 2019, and reimbursement for certain legal fees incurred in connection with the Charak MSA. The Company recorded $1.1 million as Research and Development Expense – License Acquired (Related Party) for the twelve months ended December 31, 2018. As of September 30, 2019, the Company paid all four of the quarterly installments totaling $1.0 million and accrued $0.1 million for the reimbursement of certain legal expenses. As of September 30, 2019 and December 31, 2018, the Company accrued $0.1 million and $850,000, respectively, as a related party payable on the condensed consolidated balance sheet. Pursuant to the Charak MSA, the aforementioned parties entered into an Amendment, dated as of October 7, 2018 (the “Charak Amendment”), to the Licensing Agreement between the Company and Charak, dated January 7, 2002, as amended (the “2002 Agreement”), under which Charak granted the Company an exclusive, worldwide, non-transferable license to commercialize SFP for the treatment of patients with renal failure. The Charak Amendment amends the royalty payments due to Charak under the 2002 Agreement such that the Company is liable to pay Charak royalties on net sales by the Company of products developed under the license, which includes the Company’s Triferic® product, at a specified rate until December 31, 2021 and thereafter at a reduced rate from January 1, 2022 until February 1, 2034. Additionally, the Company shall pay Charak a percentage of any sublicense income during the term of the agreement, which amount shall not be less than a minimum specified percentage of net sales of the licensed products by the sub-licensee in jurisdictions where there exists a valid claim, on a country-by-country basis, and be no less than a lower rate of the net sales of the licensed products by the sub-licensee in jurisdictions where there exists no valid claim, on a country-by-country basis. Also pursuant to the Charak MSA, the Company and Charak entered into a Commercialization and Technology License Agreement I.V. Triferic®, dated as of October 7, 2018 (the “IV Agreement”), under which Charak granted the Company an exclusive, sublicensable, royalty-bearing license to SFP for the purpose of commercializing certain intravenous-delivered products incorporating SFP for the treatment of iron disorders worldwide for a term that expires on the later of February 1, 2034 or upon the expiration or termination of a valid claim of a licensed patent. The Company is liable to pay Charak royalties on net sales by the Company of products developed under the license at a specified rate until December 31, 2021. From January 1, 2022 until February 1, 2034, the Company is liable to pay Charak a base royalty at a reduced rate on net sales and an additional royalty on net sales while there exists a valid claim of a licensed patent, on a country-by-country basis. The Company shall also pay to Charak a percentage of any sublicense income received during the term of the IV Agreement, which amount shall not be less than a minimum specified percentage of net sales of the licensed products by the sub-licensee in jurisdictions where there exists a valid claim, on a country-by-country basis, and not be less than a lower rate of the net sales of the licensed products by the sub-licensee in jurisdictions where there exists no valid claim, on a country-by-country basis. Also pursuant to the Charak MSA, the Company and Charak entered into a Technology License Agreement TPN Triferic®, dated as of October 7, 2018 (the “TPN Agreement”), pursuant to which Charak granted the Company an exclusive, sublicensable, royalty-bearing license to SFP for the purpose of commercializing worldwide certain parenteral nutritional (TPN”) products incorporating SFP. The license grant under the TPN Agreement continues for a term that expires on the later of February 1, 2034 or upon the expiration or termination of a valid claim of a licensed patent. During the term of the TPN Agreement, the Company is liable to pay Charak a base royalty on net sales and an additional royalty on net sales while there exists a valid claim of a licensed patent, on a country-by-country basis. The Company shall also pay to Charak a percentage of any sublicense income received during the term of the TPN Agreement, which amount shall not be less than a minimum royalty on net sales of the licensed products by the sub-licensee in jurisdictions where there exists a valid claim, on a country-by-country basis, and not be less than a lower rate of the net sales of the licensed products by the sub-licensee in jurisdictions where there exists no valid claim, on a country-by-country basis. The transaction was accounted for as an asset acquisition pursuant to ASU 2017-01, Business Combinations (Topic 805), Clarifying the Definition of a Business, as the majority of the fair value of the assets acquired was concentrated in a group of similar assets, and the acquired assets did not have outputs or employees. The assets acquired under the MSA include a license of SFP. Because SFP has not yet received regulatory approval, the $1.1 million purchase price paid and accrued for these assets has been expensed in the Company’s statement of operations for the year ended December 31, 2018. In addition, the potential milestone payments are not yet considered probable, and no milestone payments have been accrued at September 30, 2019.

Leases

Leases	9 Months Ended
	Sep. 30, 2019
Leases
Leases	14. Leases We lease our production facilities and administrative offices as well as certain equipment used in our operations including leases on transportation equipment used in the delivery of our products. The lease terms range from monthly to seven years. We occupy a 51,000 square foot facility and a 17,500 square foot facility in Wixom, Michigan under a lease expiring in August 2021. We also occupy two other manufacturing facilities, a 51,000 square foot facility in Grapevine, Texas under a lease expiring in December 2020, and a 57,000 square foot facility in Greer, South Carolina under a lease expiring February 2020. In addition, we occupy a 1,408 square foot office space in Greer, South Carolina under a lease expiring April 2021 and on December 28, 2018 we executed a lease for 4,100 square feet of office space in Hackensack, New Jersey with a lease term commencing in July 2019 and expiring on July 1, 2024. At September 30, 2019, the Company had operating lease liabilities of $3.0 million and right-of-use assets of $3.0 million, which are included in the consolidated balance sheet. The following summarizes quantitative information about the Company’s operating leases: Three Months Ended Nine Months Ended September 30, 2019 September 30, 2019 Operating leases Operating lease cost $ 531,709 $ 1,591,686 Variable lease cost 90,411 258,492 Operating lease expense 622,120 1,850,178 Short-term lease rent expense 4,157 12,470 Total rent expense $ 626,277 $ 1,862,648 Other information Operating cash flows from operating leases $ 493,872 $ 1,531,953 Right of use assets exchanged for operating lease liabilities $ 136,124 $ 4,441,553 Weighted-average remaining lease term – operating leases 1.8 1.8 Weighted-average discount rate – operating leases Future minimum rental payments under operating lease agreements are as follows: Three months ended December 31, 2019 $ 479,345 Year ending December 31, 2020 1,433,260 Year ending December 31, 2021 811,097 Year ending December 31, 2022 346,649 Year ending December 31, 2023 197,130 Year ending December 31, 2024 97,423 Total $ 3,364,904 Less present value discount (293,365) Operating lease liabilities $ 3,071,539

Settlement Agreement

Settlement Agreement	9 Months Ended
	Sep. 30, 2019
Settlement Agreement
Settlement Agreement	15. Settlement Agreements On August 7, 2018, the Company entered into a confidential settlement agreement and mutual release (the “Settlement Agreement”) with its former CEO, former CFO and a former and then current director. For more details see Note 10 in Form 10-K filed on March 18, 2019. This resulted in a net settlement expense of approximately $1.0 million for the nine month ended September 30, 2018. On August 7, 2019, the Company entered into a settlement agreement relating to the class action lawsuits described below. This resulted in a settlement expense of approximately $0.4 million for the nine months ended September 30, 2019. See Note 16 below for further details. The settlement is subject to court review and approval, which is scheduled for February, 2020.

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
	Sep. 30, 2019
Commitments and Contingencies.
Commitments and Contingencies	16. Commitments and Contingencies Litigation SEC Investigation As a follow up to certain prior inquiries, the Company received a subpoena from the SEC during the Company’s quarter ended September 30, 2018 requesting, among other things, certain information and documents relating to the status of the Company’s request to the CMS for separate reimbursement status for Dialysate Triferic, the Company’s reserving methodology for expiring Triferic inventory, and the basis for the Board’s termination of the former CEO and CFO. The Company is cooperating with the SEC and is responding to the SEC’s requests for documents and information. Shareholder Class Action Lawsuits On July 27, 2018, Plaintiff Ah Kit Too filed a putative class action lawsuit in the United States District Court in the Eastern District of New York against the Company and former officers, Robert Chioini and Thomas Klema. The complaint is a federal securities class action purportedly brought on behalf of a class consisting of all persons and entities, other than Defendants, who purchased or otherwise acquired the publicly traded securities of the Company between March 16, 2018 and June 26, 2018. The Complaint alleges that the Company and Messrs. Chioini and Klema violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the “Exchange Act”). Specifically, the Complaint alleges that defendants filed reports with the Securities and Exchange Commission that contained purported inaccurate and misleading statements regarding the potential for the Company’s drug, Triferic, to quality for separate reimbursement status by the Centers for Medicare and Medicaid Services. On September 4, 2018, Plaintiff Robert Spock filed a similar putative class action lawsuit in the United States District Court in the Eastern District of New York against the Company and Messrs. Chioini and Klema. The Spock complaint is a federal securities class action purportedly brought on behalf of a class consisting of persons who purchased the Company’s securities between November 8, 2017 and June 26, 2018. This complaint alleges that the Company and Messrs. Chioini and Klema violated the Exchange Act in that the Company was aware the Centers for Medicare and Medicaid Services would not pursue the Company’s proposal for separate reimbursement for Triferic; misstated reserves in the Company’s quarterly report for the first quarter of 2018; had a material weakness its internal controls over financial reporting, which rendered those controls ineffective; Mr. Chioini withheld material information regarding Triferic from the Company’s auditor, corporate counsel, and independent directors of the Board; and, as a result of these alleged issues, statements about the Company’s business were materially false and misleading. On September 25, 2018, four Company stockholders filed motions to appoint lead plaintiffs, lead counsel, and to consolidate the Ah Kit Too v. Rockwell securities class action with the Spock v. Rockwell securities class action. On October 10, 2018, the court issued an order consolidating the two actions, appointing co-lead plaintiffs and co-lead counsel. On December 10, 2018, lead Plaintiffs filed a consolidated amended complaint, which included the same allegations as the initial complaints and asserted claims on behalf of a putative class consisting of person who purchased the Company’s securities between November 8, 2017 and June 26, 2018, accordingly. On August 7, 2019, all parties to the class action entered into a settlement of the consolidated class action. Pursuant to the terms and conditions of the settlement agreement, the Company will pay the Plaintiffs $3.7 million (the “Settlement Amount’) in exchange for a full release of all liability as to all defendants. Of the Settlement Amount, the Company will be contributing approximately $0.4 million, which represents the remaining retention amount under the Company’s director and officer liability insurance policy. The remainder of the settlement amount will be funded by the Company’s director and officer insurance policy. The settlement is subject to court review and approval, which is scheduled for February, 2020. Shareholder Derivative Actions Two verified stockholder derivative complaints (the “Derivative Complaints”) entitled LeClair v Rockwell Medical, Inc., and Post v Rockwell Medical, Inc. were filed in the United States District Court in the Eastern District of New York, purportedly on behalf of the Company (as nominal defendant) and against certain of the Company’s current and former directors (the “Individual Defendants”). The Derivative Complaints assert causes of actions against the Individual Defendants for breach of fiduciary duty, waste of corporate assets, and unjust enrichment. The Derivative Complaints allege the Individual Defendants breached duties by, among other things, permitting alleged misstatements to be made in public filings regarding the status of separate reimbursement for Triferic from CMS, the adequacy of Rockwell’s reserves, and the adequacy of Rockwell’s internal controls. Recently, the Plaintiffs have amended their derivative complaints. These cases are at an early stage, and the Company anticipates filing a motion to dismiss the action. The Company has tendered the above shareholder derivative actions to its D&O insurance carrier(s) for defense and indemnity under its applicable insurance policies. The Company maintains a $1.0 million self-insured retention under the applicable insurance policies, which will be exhausted upon payment of the Company’s share of the Settlement Amount from the settlement of the class action described above.

Subsequent Events

Subsequent Events	9 Months Ended
	Sep. 30, 2019
Subsequent Events
Subsequent Events	17. Subsequent Events On October 31, 2019, CMS issued a final rule to update payment policies and rates under the ESRD Prospective Payment System for renal dialysis services furnished to beneficiaries on or after January 1, 2020 (the “2020 Final Rule”). The Final Rule contains certain revisions to the eligibility requirements for the CMS Transitional Drug Add-on Payment Adjustment (“TDAPA”) program, which has the potential to provide two years of add-on reimbursement for certain qualifying new drugs. Under the revisions to the TDAPA rules, ESRD drugs approved by the FDA under the following types of New Drug Applications (an “NDA”) are ineligible for TDAPA, effective as of January 1, 2020: (a) NDA Types 3, 5, 7 and 8, (b) NDA Type 3 in combination with NDA Type 2 or NDA Type 4, (c) NDA Type 5 in combination with NDA Type 2, or (d) NDA Type 9, when the “parent NDA” is NDA Type 3, 5, 7 or 8. As previously disclosed, we have filed an NDA for the intravenous formulation of Triferic. The FDA has informed the Company that the NDA for I.V. Triferic will be classified as Type 3. As a result, the Company believes that I.V. Triferic will not be eligible for TDAPA.

Basis of Presentation, Summar_2

Basis of Presentation, Summary of Significant Accounting Policies and Recent Accounting Pronouncements (Policies)	9 Months Ended
	Sep. 30, 2019
Basis of Presentation, Summary of Significant Accounting Policies and Recent Accounting Pronouncements
Use of Estimates	Use of Estimates The preparation of the condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that may affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of expenses during the reporting period. Actual results could differ from those estimates.
Leases	Leases Effective January 1, 2019, the Company accounts for its leases under Accounting Standards Codification (“ASC”) 842, Leases . Under this guidance, arrangements meeting the definition of a lease are classified as operating or financing leases and are recorded on the consolidated balance sheet as both a right-of-use asset and lease liability, calculated by discounting fixed lease payments over the lease term at the rate implicit in the lease or the Company’s incremental borrowing rate. Lease liabilities are increased by interest and reduced by payments each period, and the right-of-use asset is amortized over the lease term. For operating leases, interest on the lease liability and the amortization of the right-of-use asset result in straight-line rent expense over the lease term. Variable lease expenses, if any, are recorded when incurred. In calculating the right-of-use asset and lease liability, the Company elects to combine lease and non-lease components. The Company excludes short-term leases having initial terms of 12 months or less from the new guidance as an accounting policy election and recognizes rent expense on a straight-line basis over the lease term. The Company continues to account for leases in the prior period financial statements in accordance with ASC Topic 840.
Loss Per Share	Loss Per Share ASC 260, Earnings Per Share, requires dual presentation of basic and diluted earnings per share (“EPS”), with a reconciliation of the numerator and denominator of the basic EPS computation to the numerator and denominator of the diluted EPS computation. Basic EPS excludes dilution. Diluted EPS reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common stock or resulted in the issuance of common stock that are then sharing in the earnings of the entity. Basic net loss per share of common stock excludes dilution and is computed by dividing the net loss by the weighted average number of shares outstanding during the period. Diluted net loss per share of common stock reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common stock or resulted in the issuance of common stock that then shared in the earnings of the entity unless inclusion of such shares would be anti-dilutive. The Company has only incurred losses, therefore, basic and diluted net loss per share is the same. Securities that could potentially dilute net income per share in the future that were not included in the computation of diluted loss per share were as follows: As of September 30, 2019 2018 Options to purchase common stock 8,170,382 8,048,105 Unvested restricted stock awards 146,800 146,800 Unvested restricted stock units 1,324,172 1,293,750 Warrants to purchase common stock 2,770,781 - 12,412,135 9,488,655
Adoption of Recent Accounting Pronouncements	Adoption of Recent Accounting Pronouncements The Company continually assesses any new accounting pronouncements to determine their applicability. When it is determined that a new accounting pronouncement affects the Company’s financial reporting, the Company undertakes a review to determine the consequences of the change to its consolidated financial statements and assures that there are sufficient controls in place to ascertain that the Company’s consolidated financial statements properly reflect the change. In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842) , which amended the guidance on accounting for leases. The FASB issued this update to increase transparency and comparability among organizations. This update requires the recognition of lease assets and lease liabilities on the balance sheet and the disclosure of key information about leasing arrangements. The Company adopted this ASU effective January 1, 2019 using the additional (optional) approach by recording a right-of-use asset and a lease liability of approximately $3.5 million. Our adoption of this ASU had no effect on opening retained earnings, and the Company continues to account for leases in the prior period consolidated financial statements under ASC Topic 840. In adopting the new standard, the Company elected to apply the practical expedients regarding identification of leases, lease classification, indirect costs, and the combination of lease and non-lease components. In June 2018, the FASB issued ASU 2018-17, Improvements to Nonemployee Share-Based Payment Accounting, which simplifies the accounting for share-based payments granted to nonemployees for goods and services. Under ASU 2018-17, most of the guidance on such payments to nonemployees would be aligned with the requirements for share-based payments granted to employees. The amendments are effective for fiscal years beginning after December 15, 2019, and interim periods within fiscal years beginning after December 15, 2020. Early adoption is permitted, but no earlier than an entity’s adoption of Topic 606. The Company adopted this new standard on January 1, 2019 and the adoption did not have a material impact on its condensed consolidated financial statements and related disclosures.

Basis of Presentation, Summar_3

Basis of Presentation, Summary of Significant Accounting Policies and Recent Accounting Pronouncements (Tables)	9 Months Ended
	Sep. 30, 2019
Basis of Presentation, Summary of Significant Accounting Policies and Recent Accounting Pronouncements
Summary of potentially dilutive securities	As of September 30, 2019 2018 Options to purchase common stock 8,170,382 8,048,105 Unvested restricted stock awards 146,800 146,800 Unvested restricted stock units 1,324,172 1,293,750 Warrants to purchase common stock 2,770,781 - 12,412,135 9,488,655

Revenue Recognition (Tables)

Revenue Recognition (Tables)	9 Months Ended
	Sep. 30, 2019
Revenue Recognition
Disaggregation Of Revenue	In thousands of US dollars ($) Three Months Ended September 30, 2019 Nine Months Ended September 30, 2019 Products By Geographic Area Total U.S. Rest of World Total U.S. Rest of World Drug Revenues Product Sales – Point-in-time $ 98 $ 98 $ - $ 112 $ 112 $ - License Fee – Over time 68 - 68 205 - 205 Total Drug Products 166 98 68 317 112 205 Concentrate Products Product Sales – Point-in-time 14,746 13,353 1,393 44,010 39,100 4,910 License Fee – Over time 495 495 - 1,485 1,485 - Total Concentrate Products 15,241 13,848 1,393 45,495 40,585 4,910 Net Revenue $ 15,407 $ 13,946 $ 1,461 $ 45,812 $ 40,697 $ 5,115 Three Months Ended September 30, 2018 Nine Months Ended September 30, 2018 Products By Geographic Area Total U.S. Rest of World Total U.S. Rest of World Drug Revenues License Fee – Over time $ 68 - $ 68 $ 205 - $ 205 Concentrate Products Product Sales – Point-in-time 16,099 13,208 2,891 44,815 38,536 6,279 License Fee – Over time 505 505 - 1,514 1,514 - Total Concentrate Products 16,604 13,713 2,891 46,329 40,050 6,279 Net Revenue $ 16,672 $ 13,713 $ 2,959 $ 46,534 $ 40,050 $ 6,484
Contract Balances	In thousands of US dollars ($) September 30, 2019 December 31, 2018 Receivables, which are included in "Trade and other receivables" $ 5,122 $ 6,980 Contract liabilities $ 12,640 $ 14,329

Investments - Available-for-S_2

Investments - Available-for-Sale (Tables)	9 Months Ended
	Sep. 30, 2019
Investments - Available-for-Sale
Investments Available for Sale	September 30, 2019 Amortized Cost Unrealized Gain Unrealized Loss Fair Value Available-for-Sale Securities Bonds $ 14,549,799 $ 26,401 $ (611) $ 14,575,589 December 31, 2018 Amortized Cost Unrealized Gain Unrealized Loss Fair Value Available-for-Sale Securities Bonds $ 10,801,836 $ 17,415 $ (1,192) $ 10,818,059

Inventory (Tables)

Inventory (Tables)	9 Months Ended
	Sep. 30, 2019
Inventory
Schedule components of inventory	September 30, December 31, 2019 2018 Raw Materials $ 2,390,179 $ 3,621,548 Work in Process 209,940 256,129 Finished Goods 1,511,333 1,798,101 Total $ 4,111,452 $ 5,675,778

Property And Equipment (Tables)

Property And Equipment (Tables)	9 Months Ended
	Sep. 30, 2019
Property and Equipment
Schedule of major classes of property and equipment, stated at cost	September 30, December 31, 2019 2018 Leasehold Improvements $ 1,114,503 $ 929,849 Machinery and Equipment 4,719,132 4,800,774 Information Technology & Office Equipment 1,810,246 2,459,832 Laboratory Equipment 653,075 668,977 8,296,956 8,859,432 Accumulated Depreciation (5,790,863) (6,221,139) Net Property and Equipment $ 2,506,093 $ 2,638,293

Accrued Liabilities (Tables)

Accrued Liabilities (Tables)	9 Months Ended
	Sep. 30, 2019
Accrued Liabilities
Schedule of accrued liabilities	September 30, December 31, 2019 2018 Accrued Research & Development Expense $ 84,798 $ 86,820 Accrued Compensation and Benefits 1,334,563 1,525,599 Accrued Legal Expenses 392,869 170,334 Accrued Marketing Expenses 206,649 5,000 Other Accrued Liabilities 1,897,190 3,342,008 Total Accrued Liabilities $ 3,916,069 $ 5,129,761

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	9 Months Ended
	Sep. 30, 2019
Stock-Based Compensation
Schedule of total stock-based compensation expense	Three Months Ended Nine Months Ended September 30, September 30, 2019 2018 2019 2018 Service based awards: Restricted stock awards $ - $ 20,222 $ - $ 1,292,125 Restricted stock units 502,080 166,417 1,273,903 166,417 Stock option awards 596,657 427,944 1,795,819 967,377 1,098,737 614,583 3,069,722 2,425,919 Performance based awards: Restricted stock units (332,389) - 468,814 - Stock option awards 110,065 - 356,505 - (222,324) - 825,319 - Total $ 876,413 $ 614,583 $ 3,895,041 $ 2,425,919
Schedule of restricted stock award	A summary of the Company’s restricted stock awards during the nine months ended September 30, 2019 is as follows: Weighted Average Grant-Date Number of Shares Fair Value Unvested at December 31, 2018 $ 5.70 Unvested at September 30, 2019 $ 5.70 A summary of the Company’s restricted stock awards during the nine months ended September 30, 2018 is as follows: Weighted Average Grant-Date Number of Shares Fair Value Unvested at December 31, 2017 480,000 $ 7.27 Forfeited (333,200) 5.70 Unvested at September 30, 2018 146,800 $ 5.70
Restricted stock units - Service based awards
Stock-Based Compensation
Schedule of restricted stock award	Weighted Average Grant-Date Number of Shares Fair Value Unvested at December 31, 2018 472,959 $ 4.32 Granted 222,497 4.26 Forfeited (4,950) 4.81 Vested (96,542) 4.70 Unvested at September 30, 2019 593,964 $ 4.23
Restricted stock units - Performance based awards
Stock-Based Compensation
Schedule of restricted stock award	Weighted Average Grant-Date Number of Shares Fair Value Unvested at December 31, 2018 988,958 $ 4.48 Unvested at September 30, 2019 988,958 $ 4.48
Stock option awards - Service based awards
Stock-Based Compensation
Schedule of stock options activity	A summary of the Company’s service based stock option activity for the nine months ended September 30, 2019 is as follows: Weighted Weighted Average Shares Average Remaining Aggregate Underlying Exercise Contractual Intrinsic Options Price Term Value Outstanding at December 31, 2018 7,856,480 $ 7.50 5.2 $ - Granted 576,477 4.17 9.2 12,074 Exercised (30,000) 4.93 - - Forfeited (620,700) 6.34 - - Outstanding at September 30, 2019 7,782,257 $ 7.35 5.1 $ 12,074 Exercisable at September 30, 2019 6,340,901 $ 8.07 4.2 $ - A summary of the Company’s service based stock option activity for the nine months ended September 30, 2018 is as follows: Weighted Weighted Average Shares Average Remaining Aggregate Underlying Exercise Contractual Intrinsic Options Price Term Value Outstanding at December 31, 2017 6,906,001 $ 7.92 5.0 $ 976,335 Granted 1,337,271 4.96 9.4 Exercised (5,000) 6.59 - Forfeited (190,167) 6.59 - Outstanding at September 30, 2018 8,048,105 $ 7.46 5.2 $ 365,135 Exercisable at September 30, 2018 6,248,160 $ 7.90 4.1 $ 365,135
Schedule of Stock Option Assumptions	Nine Months Ended September 30, 2019 2018 Exercise price $2.39 - $6.21 $4.52 - $5.75 Expected stock price volatility 67.5% - 70.3% 67.5% Risk-free interest rate 1.4% - 2.6% 2.7% - 2.9% Term (years) 5.25 - 6.5 5.0 - 6.5
Stock option awards - Performance based awards
Stock-Based Compensation
Schedule of stock options activity	Weighted Average Exercise Number of Shares Price Outstanding at December 31, 2018 388,125 $ 4.70 Outstanding at September 30, 2019 388,125 $ 4.70 Exercisable at September 30, 2019 - $ -

Leases (Tables)

Leases (Tables)	9 Months Ended
	Sep. 30, 2019
Leases
Summary of Operating Leases	Three Months Ended Nine Months Ended September 30, 2019 September 30, 2019 Operating leases Operating lease cost $ 531,709 $ 1,591,686 Variable lease cost 90,411 258,492 Operating lease expense 622,120 1,850,178 Short-term lease rent expense 4,157 12,470 Total rent expense $ 626,277 $ 1,862,648 Other information Operating cash flows from operating leases $ 493,872 $ 1,531,953 Right of use assets exchanged for operating lease liabilities $ 136,124 $ 4,441,553 Weighted-average remaining lease term – operating leases 1.8 1.8 Weighted-average discount rate – operating leases
Future Minimum Rental Payments Under Operating Leases	Three months ended December 31, 2019 $ 479,345 Year ending December 31, 2020 1,433,260 Year ending December 31, 2021 811,097 Year ending December 31, 2022 346,649 Year ending December 31, 2023 197,130 Year ending December 31, 2024 97,423 Total $ 3,364,904 Less present value discount (293,365) Operating lease liabilities $ 3,071,539

Going Concern (Details)

Going Concern (Details) - USD ($)	Jul. 09, 2019	Jun. 20, 2019	Jun. 17, 2019	Mar. 22, 2019	Apr. 30, 2019	Sep. 30, 2019	Sep. 30, 2018	Dec. 31, 2018
Cash and cash equivalents						$ 14,421,394		$ 22,713,980
Investments available-for -sale						14,575,589		10,818,059
Working capital						28,200,000
Accumulated deficit						(299,213,836)		$ (272,388,234)
Net cash used in operating activities						$ (21,953,959)	$ (14,635,691)
Proceeds from the issuance of common stock					$ 2,296,235
Common stock, no par value ( in dollars per share)						$ 0.0001		$ 0.0001
Remaining common stock value available for issuance						$ 37,700,000
Maximum
Sales agreement				$ 40,000,000
Public offering
Number of shares issued		5,833,334
Price per share		$ 3
Proceeds from the issuance of common stock		$ 16,100,000				$ 18,777,642
Over allotment
Number of shares issued	425,800
Price per share	$ 3
Proceeds from the issuance of common stock	$ 1,200,000
Sales agreement			$ 875,000

Basis of Presentation, Summar_4

Basis of Presentation, Summary of Significant Accounting Policies and Recent Accounting Pronouncements (Details) - $ / shares	Sep. 30, 2019	Dec. 31, 2018
Basis of Presentation, Summary of Significant Accounting Policies and Recent Accounting Pronouncements
Common Shares, Shares Authorized	170,000,000	170,000,000
Common stock, no par value ( in dollars per share)	$ 0.0001	$ 0.0001
Preferred Shares, shares authorized	2,000,000	2,000,000
Preferred Shares, par value (in dollars per share)	$ 0.0001	$ 0.0001

Basis of Presentation, Summar_5

Basis of Presentation, Summary of Significant Accounting Policies and Recent Accounting Pronouncements - Loss Per Share (Details) - shares	9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018
Net Earnings per Share
Securities excluded from diluted loss per share calculation	12,412,135	9,488,655
Employee stock options
Net Earnings per Share
Securities excluded from diluted loss per share calculation	8,170,382	8,048,105
Restricted stock awards
Net Earnings per Share
Securities excluded from diluted loss per share calculation	146,800	146,800
Restricted stock units
Net Earnings per Share
Securities excluded from diluted loss per share calculation	1,324,172	1,293,750
Warrants
Net Earnings per Share
Securities excluded from diluted loss per share calculation	2,770,781

Basis of Presentation, Summar_6

Basis of Presentation, Summary of Significant Accounting Policies and Recent Accounting Pronouncements - Adoption of Recent Accounting Pronouncements (Details) - USD ($)	Sep. 30, 2019	Jan. 01, 2019
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Operating lease Right of use assets	$ 3,011,805
Operating lease liabilities	$ 3,071,539
ASU 2016-02
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Operating lease Right of use assets		$ 3,500,000
Operating lease liabilities		$ 3,500,000

Revenue Recognition - Nature of

Revenue Recognition - Nature of goods and services (Details)	9 Months Ended
	Sep. 30, 2019agreement
Revenue Recognition
Number of distribution and license agreements	2

Revenue Recognition - Disaggreg

Revenue Recognition - Disaggregation of Revenue (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Disaggregation of Revenue [Line Items]
Net Revenue	$ 15,407,248	$ 16,672,416	$ 45,812,475	$ 46,534,358
Concentrate Products
Disaggregation of Revenue [Line Items]
Net Revenue	15,241,000	16,604,000	45,495,000	46,329,000
Drug Products
Disaggregation of Revenue [Line Items]
Net Revenue	166,000		317,000
Product Sales | Drug Revenue
Disaggregation of Revenue [Line Items]
Net Revenue	98,000		112,000
Product Sales | Concentrate Products
Disaggregation of Revenue [Line Items]
Net Revenue	14,746,000	16,099,000	44,010,000	44,815,000
Product License Agreements | Drug Revenue
Disaggregation of Revenue [Line Items]
Net Revenue	68,000	68,000	205,000	205,000
Product License Agreements | Concentrate Products
Disaggregation of Revenue [Line Items]
Net Revenue	495,000	505,000	1,485,000	1,514,000
United States
Disaggregation of Revenue [Line Items]
Net Revenue	13,946,000	13,713,000	40,697,000	40,050,000
United States | Concentrate Products
Disaggregation of Revenue [Line Items]
Net Revenue	13,848,000	13,713,000	40,585,000	40,050,000
United States | Drug Products
Disaggregation of Revenue [Line Items]
Net Revenue	98,000		112,000
United States | Product Sales | Drug Revenue
Disaggregation of Revenue [Line Items]
Net Revenue	98,000		112,000
United States | Product Sales | Concentrate Products
Disaggregation of Revenue [Line Items]
Net Revenue	13,353,000	13,208,000	39,100,000	38,536,000
United States | Product License Agreements | Concentrate Products
Disaggregation of Revenue [Line Items]
Net Revenue	495,000	505,000	1,485,000	1,514,000
Rest of World
Disaggregation of Revenue [Line Items]
Net Revenue	1,461,000	2,959,000	5,115,000	6,484,000
Rest of World | Concentrate Products
Disaggregation of Revenue [Line Items]
Net Revenue	1,393,000	2,891,000	4,910,000	6,279,000
Rest of World | Drug Products
Disaggregation of Revenue [Line Items]
Net Revenue	68,000		205,000
Rest of World | Product Sales | Concentrate Products
Disaggregation of Revenue [Line Items]
Net Revenue	1,393,000	2,891,000	4,910,000	6,279,000
Rest of World | Product License Agreements | Drug Revenue
Disaggregation of Revenue [Line Items]
Net Revenue	$ 68,000	$ 68,000	$ 205,000	$ 205,000

Revenue Recognition - Contract

Revenue Recognition - Contract Balances (Details) - USD ($)	Sep. 30, 2019	Dec. 31, 2018
Revenue Recognition
Receivables, which are included in "Trade and other receivables"	$ 5,122	$ 6,980
Contract liabilities	$ 12,640	$ 14,329

Revenue Recognition - Narrative

Revenue Recognition - Narrative (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018	Dec. 31, 2018
Revenue Recognition [Line Items]
Impairment losses	$ 0	$ 0	$ 0	$ 0
Bad-debt expense	0	$ 0	0	$ 0
Contract assets	0		0		$ 0
Revenue performance obligation	10,400,000		$ 10,400,000
Remaining performance obligation practical expedient			true
Concentrate Products
Revenue Recognition [Line Items]
Reserve for returns	0		$ 0		$ 0
Baxter Healthcare Organization
Revenue Recognition [Line Items]
Revenue performance obligation	$ 9,600,000		$ 9,600,000

Investments - Available-for-S_3

Investments - Available-for-Sale (Details) - USD ($)	9 Months Ended	12 Months Ended
	Sep. 30, 2019	Dec. 31, 2018
Investments - Available-for-Sale
Amortized Cost	$ 14,549,799	$ 10,801,836
Unrealized Gains	26,401	17,415
Unrealized Loss	(611)	(1,192)
Fair Value	$ 14,575,589	$ 10,818,059

Inventory (Details)

Inventory (Details) - USD ($)	9 Months Ended
	Sep. 30, 2019	Dec. 31, 2018
Inventory [Line Items]
Raw Materials	$ 2,390,179	$ 3,621,548
Work in Process	209,940	256,129
Finished Goods	1,511,333	1,798,101
Total	4,111,452	5,675,778
Inventory, non-current	528,000	1,637,000
Inventory	3,583,452	4,038,778
Triferic Finished Goods
Inventory [Line Items]
Inventory, non-current	500,000	1,600,000
Inventory	700,000
finished goods sellable through 2020	100,000
finished goods sellable through 2023	600,000
Triferic Finished And Raw Goods
Inventory [Line Items]
Finished goods inventory	3,500,000	8,000,000
Inventory reserve	2,800,000	$ 5,800,000
Increase in inventory reserves	$ 1,100,000

Property And Equipment (Details

Property And Equipment (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018	Dec. 31, 2018
Property and equipment
Gross Property and Equipment	$ 8,296,956		$ 8,296,956		$ 8,859,432
Accumulated Depreciation	(5,790,863)		(5,790,863)		(6,221,139)
Net Property and Equipment	2,506,093		2,506,093		2,638,293
Depreciation expense	200,000	$ 200,000	580,000	$ 470,000
Leasehold Improvements
Property and equipment
Gross Property and Equipment	1,114,503		1,114,503		929,849
Machinery and Equipment
Property and equipment
Gross Property and Equipment	4,719,132		4,719,132		4,800,774
Information Technology & Office Equipment
Property and equipment
Gross Property and Equipment	1,810,246		1,810,246		2,459,832
Laboratory Equipment
Property and equipment
Gross Property and Equipment	$ 653,075		$ 653,075		$ 668,977

Accrued Liabilities (Details)

Accrued Liabilities (Details) - USD ($)	Sep. 30, 2019	Dec. 31, 2018
Accrued Liabilities
Accrued Research & Development Expense	$ 84,798	$ 86,820
Accrued Compensation and Benefits	1,334,563	1,525,599
Accrued Legal Expenses	392,869	170,334
Accrued Marketing Expenses	206,649	5,000
Other Accrued Liabilities	1,897,190	3,342,008
Total Accrued Liabilities	$ 3,916,069	$ 5,129,761

Insurance Financing Note Paya_2

Insurance Financing Note Payable (Details) - USD ($)	Jul. 03, 2019	Sep. 30, 2019	Jun. 03, 2019
Insurance Financing Note Payable [Abstract]
Short-term note payable			$ 1,900,000
Interest rate per annum			4.65%
Amortization period (in months)	10 months
Insurance notes payable		$ 1,145,133

Deferred Revenue (Details)

Deferred Revenue (Details) - USD ($) $ in Millions	1 Months Ended	3 Months Ended		9 Months Ended		12 Months Ended
	Oct. 31, 2014	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018	Dec. 31, 2016	Dec. 31, 2018
Deferred Revenue Arrangement [Line Items]
Upfront payment						$ 4
Wanbang Biopharmaceutical
Deferred Revenue Arrangement [Line Items]
Distribution agreement term	10 years
Recognized deferred revenue		$ 0.1	$ 0.1	$ 0.2	$ 0.2
Deferred Revenue		3		3			$ 3.2
Baxter Healthcare Organization
Deferred Revenue Arrangement [Line Items]
Upfront payment	$ 20
Recognized deferred revenue		0.5	$ 0.5	1.5	$ 1.5
Deferred Revenue		$ 9.6		$ 9.6			$ 11.1
Deferred Revenue Benefit Percentage				25.00%
Partial Refund				$ 6.6

Stockholders_ Equity (Details)

Stockholders’ Equity (Details) - USD ($)	Jul. 09, 2019	Jun. 20, 2019	Jun. 17, 2019	Mar. 22, 2019	Apr. 30, 2019	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018	Jul. 30, 2019	Jun. 06, 2019	Dec. 31, 2018
Preferred Stock
Preferred stock, Authorized						2,000,000		2,000,000				2,000,000
Preferred Stock, Par or Stated Value Per Share						$ 0.0001		$ 0.0001				$ 0.0001
Preferred stock, Outstanding						0		0				0
Preferred Stock, Shares Issued						0		0				0
Common Stock
Common Shares, Shares Authorized						170,000,000		170,000,000				170,000,000
Common Stock, Par or Stated Value Per Share						$ 0.0001		$ 0.0001				$ 0.0001
Common stock issued on exercise of stock options (in shares)								30,000
Amount of common stock issued on exercise of stock options							$ (1,978)	$ 147,900	$ (1,978)
Average exercise price of options exercised (in dollars per share)					$ 5.25			$ 4.93
Common shares sold					437,043	63,887,384		63,887,384				57,034,154
Remaining common stock value available for issuance						$ 37,700,000		$ 37,700,000
Controlled Equity Offering
Proceeds from the issuance of common stock					$ 2,296,235
Payment of commissions and offering fees					$ 207,027
Underwriter and legal fees		$ 1,379,323
Common Stock, Par or Stated Value Per Share						$ 0.0001		$ 0.0001				$ 0.0001
Restricted Common Stock
Vested restricted stock								96,542
Maximum
Controlled Equity Offering
Sales agreement				$ 40,000,000
Restricted stock units | Officer
Restricted Common Stock
Vested restricted stock								195,042
Withheld common shares at fair value								68,069
Cost of withheld common shares								$ 180,289
Public offering
Controlled Equity Offering
Gross proceeds from issuance of common stock		17,500,002
Proceeds from the issuance of common stock		$ 16,100,000						18,777,642
Share price		$ 3
Payment of commissions and offering fees								$ 1,487,721
Number of shares issued		5,833,334
Public offering | Maximum
Common Stock
Common Shares, Shares Authorized			6,708,334
Over allotment
Controlled Equity Offering
Sales agreement			$ 875,000
Proceeds from the issuance of common stock	$ 1,200,000
Share price	$ 3
Number of shares issued	425,800
COMMON SHARES
Common Stock
Common Shares, Shares Authorized						170,000,000		170,000,000
Increase of common shares authorized											50,000,000
Common stock issued on exercise of stock options (in shares)							870	30,000	870
Amount of common stock issued on exercise of stock options								$ 3
COMMON SHARES | Minimum
Common Stock
Common Shares, Shares Authorized										120,000,000	120,000,000
COMMON SHARES | Maximum
Common Stock
Common Shares, Shares Authorized										170,000,000	170,000,000
COMMON SHARES | Public offering
Controlled Equity Offering
Number of shares issued						425,880		6,259,214

Stock-Based Compensation - Shar

Stock-Based Compensation - Share-based compensation expense (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Total share-based compensation expense	$ 876,413	$ 614,583	$ 3,895,041	$ 2,425,919
Service based awards
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Total share-based compensation expense	1,098,737	614,583	3,069,722	2,425,919
Restricted stock awards - Service based awards
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Total share-based compensation expense		20,222		1,292,125
Restricted stock units - Service based awards
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Total share-based compensation expense	502,080	166,417	1,273,903	166,417
Stock option awards - Service based awards
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Total share-based compensation expense	596,657	$ 427,944	1,795,819	967,377
Performance based awards
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Total share-based compensation expense	(222,324)		825,319
Restricted stock units - Performance based awards
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Total share-based compensation expense	(332,389)		468,814
Change in share-based compensation expense	700,000		700,000
Stock option awards - Performance based awards
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Total share-based compensation expense	110,065		356,505	$ 51,000
Restricted stock awards
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Change in share-based compensation expense	$ 700,000		$ 700,000

Stock-Based Compensation - Rest

Stock-Based Compensation - Restricted Stock Awards (Details) - Restricted stock awards - $ / shares	9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Dec. 31, 2018	Dec. 31, 2017
Number of Shares
Unvested (in shares)	146,800	146,800	146,800	480,000
Forfeited (in shares)		(333,200)
Weighted Average Grant Date Fair Value
Weighted Average Grant-Date Fair Value (in dollars per shares)	$ 5.70	$ 5.70	$ 5.70	$ 7.27
Vesting period	20 months

Stock-Based Compensation - Serv

Stock-Based Compensation - Service Based Restricted Stock Units (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Number of Shares
Granted (in shares)			222,497
Forfeited (in shares)			(4,950)
Vested (in shares)			(96,542)
Weighted Average Grant Date Fair Value
Stock based compensation expenses	$ 876,413	$ 614,583	$ 3,895,041	$ 2,425,919
Restricted stock units - Service based awards
Number of Shares
Outstanding at beginning of period (in shares)			472,959
Outstanding at end of period (in shares)	593,964		593,964
Weighted Average Grant Date Fair Value
Outstanding at beginning of period (in dollars per share)			$ 4.32
Granted (in dollars per share)			4.26
Forfeited (in dollars per shares)			4.81
Vested (in dollars per share)			4.70
Outstanding at end of period (in dollars per share)	$ 4.23		$ 4.23
Stock based compensation expenses	$ 500,000		$ 1,300,000	$ 200,000
Unrecognized stock-based compensation expenses	$ 1,300,000		$ 1,300,000
Minimum | Restricted stock units - Service based awards
Weighted Average Grant Date Fair Value
Vesting period			1 year
Maximum | Restricted stock units - Service based awards
Weighted Average Grant Date Fair Value
Vesting period			3 years

Stock-Based Compensation - Perf

Stock-Based Compensation - Performance Based Restricted Stock Units (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018	Dec. 31, 2018
Weighted Average Grant Date Fair Value
Stock based compensation expenses	$ 876,413	$ 614,583	$ 3,895,041	$ 2,425,919
Restricted stock units - Performance based awards
Number of Shares
Unvested (in shares)	988,958		988,958		988,958
Weighted Average Grant Date Fair Value
Weighted Average Grant-Date Fair Value (in dollars per shares)	$ 4.48		$ 4.48		$ 4.48
Unrecognized stock-based compensation expenses	$ 1,000,000		$ 1,000,000
Change in share-based compensation expense	700,000		700,000
Stock based compensation expenses	$ (332,389)		$ 468,814

Stock-Based Compensation - Se_2

Stock-Based Compensation - Service Based Stock Options - Fair value assumptions (Details) - Stock option awards - Service based awards - $ / shares	9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected stock price volatility		67.50%
Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price	$ 2.39	$ 4.52
Expected stock price volatility	67.50%
Risk-free interest rate	1.40%	2.70%
Term (years)	5 years 3 months	5 years
Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price	$ 6.21	$ 5.75
Expected stock price volatility	70.30%
Risk-free interest rate	2.60%	2.90%
Term (years)	6 years 6 months	6 years 6 months

Stock-Based Compensation - Se_3

Stock-Based Compensation - Service Based Stock Options (Details) - USD ($)	1 Months Ended	9 Months Ended		12 Months Ended
	Apr. 30, 2019	Sep. 30, 2019	Sep. 30, 2018	Dec. 31, 2018	Dec. 31, 2017
Shares Underlying Options
Granted (in shares)		222,497
Exercised (in shares)		(30,000)
Forfeited (in shares)		(4,950)
Weighted Average Exercise Price
Exercised (in dollars per share)	$ 5.25	$ 4.93
Aggregate intrinsic Value
Granted (in dollars)		$ 12,074
Stock option awards - Service based awards
Shares Underlying Options
Outstanding at the beginning of the period (in shares)		7,856,480	6,906,001	6,906,001
Granted (in shares)		576,477	1,337,271
Exercised (in shares)		(30,000)	(5,000)
Forfeited (in shares)		(620,700)	(190,167)
Outstanding at the end of the period (in shares)		7,782,257	8,048,105	7,856,480	6,906,001
Exercisable, Shares underlying		6,340,901	6,248,160
Weighted Average Exercise Price
Outstanding at the beginning of the period (in dollars per share)		$ 7.50	$ 7.92	$ 7.92
Granted (in dollars per share)		4.17	4.96
Exercised (in dollars per share)		4.93	6.59
Forfeited (in dollars per share)		6.34	6.59
Outstanding at the end of the period (in dollars per share)		7.35	7.46	$ 7.50	$ 7.92
Exercise price (in dollars per share)		$ 8.07	$ 7.90
Weighted Average Remaining Contractual Term
Outstanding, Weighted Average Remaining Contractual Term		5 years 1 month 6 days	5 years 2 months 12 days	5 years 2 months 12 days	5 years
Granted, Weighted Average Remaining Contractual Term		9 years 2 months 12 days	9 years 4 months 24 days
Exercisable, Weighted Average Remaining Contractual Term		4 years 2 months 12 days	4 years 1 month 6 days
Aggregate intrinsic Value
Outstanding (in dollars)		$ 12,074	$ 365,135		$ 976,335
Exercise (in dollars)			$ 365,135

Stock-Based Compensation - Se_4

Stock-Based Compensation - Service Based Stock Options - Others (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Forfeited (in shares)			4,950
Allocated Share-based Compensation Expense	$ 876,413	$ 614,583	$ 3,895,041	$ 2,425,919
Stock option awards - Service based awards
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Forfeited (in shares)			620,700	190,167
Allocated Share-based Compensation Expense	596,657	$ 427,944	$ 1,795,819	$ 967,377
Unrecognized stock-based compensation expenses	$ 2,100,000		$ 2,100,000

Stock-Based Compensation - Pe_2

Stock-Based Compensation - Performance Based Stock Options (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018	Dec. 31, 2018
Weighted Average Exercise Price
Stock based compensation expenses	$ 876,413	$ 614,583	$ 3,895,041	$ 2,425,919
Stock option awards - Performance based awards
Number of Shares
Outstanding number of shares	388,125		388,125		388,125
Weighted Average Exercise Price
Weighted average exercise price	$ 4.70		$ 4.70		$ 4.70
Stock based compensation expenses	$ 110,065		$ 356,505	$ 51,000
Unrecognized stock-based compensation expenses	$ 600,000		$ 600,000

Related Party Transactions (Det

Related Party Transactions (Details)	Oct. 07, 2018USD ($)installmentitem	Sep. 30, 2019USD ($)	Sep. 30, 2018USD ($)	Dec. 31, 2018USD ($)	Jul. 15, 2019USD ($)	Apr. 15, 2019USD ($)	Jan. 15, 2019USD ($)	Oct. 15, 2018USD ($)
Settlement expense		$ 430,000	$ 1,030,000
Number of additional agreements | item	3
Product development and research costs				$ 1,100,000
Master services and IP agreements
Payments to acquire assets				1,100,000
Milestone payments		0
Executive Vice President and Chief Scientific Officer
Total amount due	$ 1,000,000	100,000		$ 850,000	$ 250,000	$ 250,000	$ 250,000	$ 250,000
Number of quarterly installment payments | installment	4
Installment paid		1,000,000
Related Party Transactions Accrued Reimbursement of Legal Expenses		$ 100,000

Leases - Narrative (Details)

Leases - Narrative (Details)	Sep. 30, 2019USD ($)ft²
Lessee, Lease, Description [Line Items]
Operating lease liabilities | $	$ 3,071,539
Operating lease Right of use assets | $	$ 3,011,805
Grapevine, Texas
Lessee, Lease, Description [Line Items]
Facility sqft.	51,000
Hackensack, New Jersey
Lessee, Lease, Description [Line Items]
Facility sqft.	4,100
Lease Facility One | Wixom, Michigan
Lessee, Lease, Description [Line Items]
Facility sqft.	51,000
Lease Facility One | Greer, South Carolina
Lessee, Lease, Description [Line Items]
Facility sqft.	57,000
Lease Facility Two | Wixom, Michigan
Lessee, Lease, Description [Line Items]
Facility sqft.	17,500
Lease Facility Two | Greer, South Carolina
Lessee, Lease, Description [Line Items]
Facility sqft.	1,408
Minimum
Lessee, Lease, Description [Line Items]
Lease Term	1 month
Maximum
Lessee, Lease, Description [Line Items]
Lease Term	7 years

Leases - Summary of Operating L

Leases - Summary of Operating Leases (Details)	3 Months Ended	9 Months Ended
	Sep. 30, 2019USD ($)	Sep. 30, 2019USD ($)
Leases
Operating lease cost	$ 531,709	$ 1,591,686
Variable lease cost	90,411	258,492
Operating lease expense	622,120	1,850,178
Short-term lease rent expense	4,157	12,470
Total rent expense	626,277	1,862,648
Operating cash flows from operating leases	493,872	1,531,953
Right of use assets exchanged for operating lease liabilities	$ 136,124	$ 4,441,553
Weighted-average remaining lease term – operating leases	1 year 9 months 18 days	1 year 9 months 18 days
Weighted-average discount rate – operating leases	6.80%	6.80%

Leases - Future Minimum Rental

Leases - Future Minimum Rental Payments Under Operating Leases (Details)	Sep. 30, 2019USD ($)
Leases
Three months ended December 31, 2019	$ 479,345
Year ending December 31, 2020	1,433,260
Year ending December 31, 2021	811,097
Year ending December 31, 2022	346,649
Year ending December 31, 2023	197,130
Year ending December 31, 2024	97,423
Total	3,364,904
Less present value discount	(293,365)
Operating lease liabilities	$ 3,071,539

Settlement Agreement (Details)

Settlement Agreement (Details) - USD ($)	Aug. 07, 2019	Sep. 30, 2019	Sep. 30, 2018
Loss Contingencies [Line Items]
Litigation settlement amount	$ 3,700,000
Settlement expense		$ 430,000	$ 1,030,000
Confidential Settlement Agreement
Loss Contingencies [Line Items]
Litigation settlement amount			$ 1,000,000
Settlement Agreement with All Parties
Loss Contingencies [Line Items]
Settlement expense		$ 400,000

Commitments and Contingencies (

Commitments and Contingencies (Details) - USD ($)	Aug. 07, 2019	Sep. 30, 2019	Sep. 30, 2018
Loss Contingencies [Line Items]
Litigation settlement amount	$ 3,700,000
Settlement expense		$ 430,000	$ 1,030,000
Self insurance retention		1,000,000
Settlement Agreement with All Parties
Loss Contingencies [Line Items]
Settlement expense		$ 400,000